Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCHN0603

Title

Effect of PI3K Inhibition in HPV Infected Cell (deidentified)

Principal Investigator(s)

Wendell Yarbrough

Details

  • Protocol No. VICCHN0603
  • Open Date: 04/28/2006
  • Staging: N/A
  • Age Group: Adults
  • Scope: Local
  • Objective: Analyses of HPV(+) and HPV(-) for PIK3CA mutations and amplification and expression of p100a PIK3CA can be activated by overexpression, amplification or mutation. To analyze the PIK3CA gene for mutation and amplification and determine protein expression in 20 HPV(+) and 20 HPV(-) oropharyngeal HNSCC
  • Disease Sites: Head/Neck
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00897988
  • Secondary Protocol No: Not Specified

Description

None Provided.

Eligibility

Ages Eligible for Study:N/A and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Criteria

DISEASE CHARACTERISTICS:
• Undergoing operative procedures for biopsy and/or resection of squamous cell carcinoma (SCC) of the oropharynx
• Tumor tissue sample available from the Head and Neck Tissue Repository and Clinical Database of Vanderbilt University
• No tumors with human papilloma virus (HPV) DNA sequences but no expression of E6
PATIENT CHARACTERISTICS:
• See Disease Characteristics
PRIOR CONCURRENT THERAPY:
• Not specified